Fuji Pharma Co Ltd (4554) Q4 2026 earnings summary

Executive summary

• FY9/26 net sales rose 20.7% to ¥62,386m; operating profit increased 27.4% to ¥6,355m and ordinary profit rose 38.5% to ¥6,176m.

• Profit attributable to owners of parent fell 5.6% to ¥2,831m, reflecting a ¥2,000m investment securities valuation loss and ¥762m impairment loss.

• Growth was supported by women's healthcare products, biosimilar launches, global CMO activity and higher hematology and gastroenterology sales.

Financial highlights

• Gross profit rose 17.1% to ¥24,321m; gross margin fell to 39.0% from 40.2% amid higher imported-product costs from currency fluctuations.

• SG&A increased 13.9% to ¥17,966m, including R&D expense up 21.4% to ¥4,059m; EBITDA rose 19.1% to ¥10,562m.

• Comprehensive income was ¥3,450m, up from ¥2,171m in FY9/25.

Outlook and guidance

• FY27 forecast: net sales ¥69,190m (+10.9%), operating profit ¥7,420m (+16.8%), ordinary profit ¥6,910m (+11.9%) and net income ¥4,880m (+72.4%).

• Domestic growth is expected from Alyssa and biosimilars; overseas expansion centers on Nextstellis in ASEAN through OLIC. R&D expense is expected to increase significantly.

• FY9/26 results reached 105.3% of revised net sales forecast, 103.8% of operating profit forecast and 105.0% of ordinary profit forecast.